Neurogene Inc. ( (NGNE) ) has released its Q3 earnings. Here is a breakdown of the information Neurogene Inc. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Neurogene Inc. is a clinical-stage biotechnology company focused on developing gene therapies for neurological diseases, utilizing its proprietary EXACT transgene regulation technology. The company recently released its earnings report for the quarter ending September 30, 2025, highlighting key financial metrics and strategic developments. Neurogene reported a net loss of $20.95 million for the quarter, with total operating expenses amounting to $23.8 million. The company’s cash and cash equivalents decreased to $71 million, down from $136.6 million at the end of 2024, while short-term investments increased to $194.4 million. Despite the losses, Neurogene’s management remains optimistic about its financial position, with cash and investments expected to support operations for at least another year. Looking ahead, Neurogene plans to continue advancing its clinical programs and exploring strategic partnerships to enhance its financial stability and support its mission of transforming neurological disease treatment.